Collectively, these data suggest that TERT-promoter-mutated FT-UMPs should be considered malignant tumors with a higher recurrence rate than miFTCs without TERT promoter mutations, but similar to that of TERT-promoter-mutated miFTCs. This evidence concerns the gene TERT and cancer.